![Marea Therapeutics Secures $190 Million to Propel Novel Cardiovascular Treatments](https://thetimesmag.com/wp-content/uploads/2024/06/20240618lnp1-executives-600x390.jpeg)
Marea Therapeutics Secures $190 Million to Propel Novel Cardiovascular Treatments
Marea Therapeutics has marked a significant milestone with the successful closure of a $190 million combined Series A and B financing, positioning the clinical-stage biotechnology firm to accelerate its pioneering efforts in cardiometabolic disease treatments. Led by Third Rock Ventures and supported by a consortium of leading investors including Sofinnova Investments, Forbion, and Perceptive Xontogeny…